GLP-1s Just Put Sleep Apnea in the Headlines. Is Your Practice Ready?
This week, sleep apnea became front-page health news again. Two phase 3 trials published in The New England Journal of Medicine showed that retatrutide, Eli Lilly's next-generation GLP-1-based weight-loss drug, sharply cut breathing interruptions during sleep in adults with moderate-to-severe obstructive sleep apnea (OSA). Fox News and other outlets ran the story on October 28, 2026.
A few months ago we wrote about the GLP-1 wave and what it means for your practice: more appearance-motivated adults, new oral side effects to screen for, and a growing tailwind around sleep apnea. This news turns that last point from a footnote into a headline. Your patients, and the parents of your patients, are going to be asking about sleep and airway. The question is whether your practice has a clear answer.
What the new study found
Retatrutide cut OSA severity by more than half in roughly two out of three patients over 80 weeks. The trials enrolled 691 adults with moderate-to-severe OSA and a BMI of 27 or higher, with and without type 2 diabetes, on weekly injections or placebo.
Measure | Result |
Body weight lost | About 12% to nearly 20% |
Patients with >50% improvement in OSA | About 68% |
Drop in hypoxic burden (low-oxygen episodes) | About 75% without diabetes, 65% with diabetes |
OSA fully resolved | About 25% without diabetes, 15% with diabetes |
Other changes | Lower blood pressure, LDL, inflammation and neck circumference; CPAP use generally declined |
Mayo Clinic cardiologist and study co-author Dr. Virend Somers called it "a very exciting time in treating sleep apnea patients."
Two caveats matter. Retatrutide is not FDA-approved, and the researchers stressed that patients should not stop CPAP or other prescribed treatment. It joins Zepbound (tirzepatide), which in December 2024 became the first drug the FDA approved for OSA in adults with obesity.
Why this matters now: The public is waking up to sleep apnea
Every GLP-1 headline about sleep apnea sends more people searching for answers. More than 50 million Americans have OSA, and the National Sleep Foundation estimates about 80% of cases are undiagnosed. Meanwhile, roughly 12% of U.S. adults (31 to 32 million people) are already on a GLP-1, per KFF's March 2026 polling.
Google Trends data cited in a 2025 study found that searches for oral appliances for sleep apnea increased by more than 200% between 2016 and 2024.
Put those together and you get a public that is newly curious about snoring, tiredness and "is this sleep apnea?" Sleep researchers are saying the same thing: wider awareness of treatment options should push more people to get screened. Those people include your adult patients, the parents in your waiting room, and the referring dentists and physicians you work with.
When patients start asking, the practices that sound informed and confident win their trust. The ones that shrug, or overpromise, lose it.
What the headlines leave out: weight isn't the whole airway story
Even with dramatic weight loss, most trial patients still had some sleep apnea at the end. OSA fully resolved in only about 1 in 4 patients without diabetes and about 1 in 7 with diabetes. For the rest, something besides weight is still narrowing the airway.
That "something" is often anatomy: jaw size and position, maxillary width, tongue posture, tonsils and adenoids, and how the craniofacial complex developed in childhood. A drug can shrink soft tissue. It doesn't widen a constricted maxilla or reposition a retruded mandible.
And GLP-1s are an adult story. Pediatric sleep-disordered breathing (mouth breathing, snoring, restless sleep, behavior and attention issues) is a growth-and-development problem, and that is squarely where orthodontists see children every day.
Even the study's own author listed mandibular devices alongside CPAP, positional therapy and the new drugs as tools for sleep apnea. Drugs are a new option. They are not the whole answer, and that leaves a real role for the orthodontist.
Where the orthodontist fits: clarity, not hype
Orthodontists don't diagnose sleep apnea; sleep physicians do. But orthodontists are often the first clinician to notice the signs, and among the few who can change the structures involved. That makes you a natural part of the care team, if you know your lane.
The practices that will stand out over the next few years are the ones that can:
Recognize sleep-disordered breathing signs in both children and adults during routine exams.
Evaluate airway-related findings responsibly, including what CBCT can and can't tell you.
Know what to say to a worried parent or a GLP-1 patient asking whether their snoring matters.
Refer at the right time to sleep physicians, ENTs and myofunctional therapists.
Collaborate so the orthodontic plan fits into a bigger treatment picture.
This is a genuine way to differentiate your practice. Patients and referring doctors remember the orthodontist who understood the whole picture.
Get clarity before your patients start asking
If this news has you wondering where your practice stands on sleep and airway, the timing couldn't be better. On December 4–5, 2026, Orthopreneurs is hosting the Sleep & Airway Meeting at the Arizona Biltmore in Phoenix: 10 hours of clinical CE focused on the orthodontist's role in sleep and airway care.
Seats are limited and only a few doctor passes remain. Reserve your spot at the Sleep & Airway Meeting →
Comments